Methicillin-resistant staphylococcus aureus (MRSA)
medical conditions

Methicillin-resistant staphylococcus aureus (MRSA)

Explore the available health information, treatment context, and integrative evidence for Methicillin-resistant staphylococcus aureus (MRSA).

Background
  • Staphylococcus aureus (S. aureus) is an extremely versatile bacterium that can cause infections ranging in severity from mild to severe in humans and animals. S. aureus is normally found on the skin or in the nasal passages of about one third of the population. Most individuals harboring S. aureus are not ill but are "colonized" with the bacteria. Individuals who are colonized with S. aureus may develop infection if the bacteria enter the body through a break in the skin or nasal passages. Individuals who are colonized have the ability to spread the organism, even if they are not ill. If the bacteria are transmitted to another individual, they may cause infection in that individual. The ability of bacteria to resist the effects of an antibiotic is called antibiotic resistance. During the past decade, antibiotic resistance has increased tremendously worldwide.
  • Methicillin is a type of penicillin that was developed in 1959 to treat infections from S. aureus and other bacteria that were resistant to earlier forms of penicillin. Since that time, however, S. aureus and other bacteria have developed resistance to methicillin. Methicillin-resistant Staphylococcus aureus (MRSA) is now a global health concern. MRSA is highly virulent and can cause a large number of serious illnesses that do not respond well to current medical treatment.
  • MRSA has adapted in ways that allow it to be resistant to a number of antibiotics, including penicillin, methicillin, and cephalosporins. This adaptation or evolution, has been accomplished by mutation of the genetic material contained in S. aureus. The mutated bacteria are less or no longer susceptible to damage from methicillin.
  • MRSA was first noted in 1961, about two years after methicillin was initially used to treat S. aureus and other infectious bacteria. The resistance to methicillin was caused by a penicillin-binding protein coded for by a mobile genetic element (MGE). An MGE is a type of genetic material that has the ability to move genetic material from one organism to another. The MRSA MGA gene is called the methicillin-resistant gene (mecA). This gene has continued to evolve and, thus, many MRSA strains are currently resistant to several different antibiotics.
  • MRSA infections commonly occur in hospitals and other healthcare facilities, such as nursing homes. MRSA acquired in a hospital is known as hospital-acquired-MRSA (HA-MRSA) and infections transmitted within a hospital are known as nosocomial infections. Patients in healthcare facilities often have had a recent bacterial infection and have received antibiotics. A number of these patients have become colonized with bacterial strains that are resistant to antibiotics. Hospital workers who care for these patients may also become colonized.
  • MRSA infections that occur in healthy people who have not undergone a medical procedure or hospitalization within the past year are known as community-associated-MRSA (CA-MRSA) infections. These infections are usually located on the skin and appear as abscesses, boils, and other pus-filled lesions. Currently 10% of all MRSA infections in the United States are CA-MRSA. Individuals with a weakened immune system are particularly susceptible to MRSA.
  • Not only has S. aureus developed resistance to methicillin, it has developed resistance to newer antibiotics. As new antibiotics are developed, it is likely that this highly-adaptable bacterium will develop resistance to them as well.
  • Research in the field of genomics may aid in the treatment of MRSA infection. As researchers gain further understanding of the MRSA genome, the outlook for patients with this disease may improve
Risk Factors and Causes
  • The two types of methicillin-resistant Staphylococcus aureus (MRSA) include community-associated MRSA and healthcare-associated MRSA.
  • Community-associated-MRSA (CA-MRSA) risk factors: Individuals with a weakened immune system, such as those who have HIV/AIDS or are undergoing chemotherapy for cancer treatment, are at increased risk of serious infection from CA-MRSA.
  • CA-MRSA is especially dangerous in children. The bacteria can enter the body through a cut or scrape and the organism can then spread throughout the body. Children and young adults are also more susceptible to a CA-MRSA-induced form of pneumonia, which is a serious illness.
  • Crowded or unsanitary living conditions increase the exposure risk to CA-MRSA. CA-MRSA outbreaks have occurred in military bases and prisons. Athletic teams have an increased risk of exposure to CA-MRSA. The organism readily spreads from cuts, scrapes, and skin-to-skin contact. It can also be contracted from shared towels, uniforms, razors, and sports equipment. Close contact with healthcare workers increases the exposure risk to CA-MRSA. Individuals with multiple sexual partners are at increased risk of acquiring CA-MRSA.
  • Healthcare-associated-MRSA (HA-MRSA) risk factors: Individuals who are currently or were recently hospitalized are at increased risk of HA-MRSA, especially if they are older or have a weakened immune system. In addition to acute care hospitals, MRSA is also common in long-term care facilities. Patients with serious illness, recent surgery, burns, and hospitalization lasting more than two weeks are also more susceptible to HA-MRSA. Recent antibiotic treatment with cephalosporin or fluoroquinolones (ciprofloxacin, levofloxacin, or ofloxacin) can increase the risk of HA-MRSA. Patients who are attached to invasive devices, such as catheters, feeding tubes, and dialysis equipment, have an increased risk of HA-MRSA. Furthermore, after hospital discharge, patients harboring MRSA can spread the infection to friends and relatives.

  • Methicillin-resistant Staphylococcus aureus (MRSA) has adapted in ways that allow it to be resistant to a number of antibiotics, including penicillin, methicillin, and cephalosporins. This adaptation or evolution, has been accomplished by mutation of the genetic material contained in S. aureus. The mutated bacteria are less or no longer susceptible to damage from methicillin.
  • MRSA was first noted in 1961, about two years after methicillin was initially used to treat S. aureus and other infectious bacteria. The resistance to methicillin was caused by a penicillin-binding protein coded for by a mobile genetic element (MGE). An MGE is a type of genetic material that has the ability to move genetic material from one organism to another. The MRSA MGA gene is called the methicillin-resistant gene (mecA). This gene has continued to evolve and, thus, many MRSA strains are currently resistant to several different antibiotics.
  • Overuse of antibiotics is a major contributor to bacterial resistance. Unnecessary or more frequent use of an antibiotic increases the chance of a resistant strain developing. Antibiotic overuse has been termed "antibiotic pressure," which increases the chance of a resistant strain developing. Bacteria sensitive to the antibiotic are destroyed while bacteria resistant to the antibiotic flourish. Using the antibiotic on a resistant strain of bacteria favors the growth of the very microorganism that treatment is intended to eliminate.
  • Antibiotic pressure may also occur indirectly through inappropriate use of antibiotics. Examples of inappropriate uses include administration to patients with a viral upper respiratory infection, which is not affected by antibiotics, and addition to animal feed to promote growth.
  • A number of studies have found that patients frequently do not complete a full course of prescribed antibiotic treatment. This can promote the development of antibiotic resistance in some bacteria because they remain in the body and allow resistance to develop. Conversely, an excessively long course of antibiotic treatment adds to the antibiotic pressure, thus favoring the development of resistant strains.
  • S. aureus toxin-mediated diseases, such as toxic shock syndrome (TSS), staphylococcal food poisoning (SFP), and staphylococcal scalded-skin syndrome (SSSS), are caused by toxins produced by the bacteria. Complete recovery is the rule for SFP and SSS, while TSS has a high mortality rate.
Signs and Symptoms
  • Staphylococcal skin infections, including methicillin-resistant Staphylococcus aureus (MRSA), often remain on the skin. However, they sometimes penetrate into the body and can cause life-threatening infections in the bloodstream, lungs, heart valves, surgical incisions, bones, and joints.
  • MRSA infections on the skin usually start as small red bumps that look like pimples, boils, or spider bites. These infections can quickly become deep, painful abscesses.
Diagnosis
  • Diagnosis of methicillin-resistant Staphylococcus aureus (MRS) is made by obtaining a culture from an infected area. Any area of the skin that has blisters, pus, or abscesses should be swabbed for MRSA. Cultures can also be obtained from the nasal passages, mouth, bone marrow, joint fluid, or surgical sites to test for MRSA.
  • Cultures are grown in a standard laboratory technique and exposed to methicillin. If Staphylococcus aureus continues to grow in the presence of methicillin, the bacteria are considered MRSA.
  • Carriers of MRSA can be diagnosed by swabbing the skin, nasal passages, or throat of individuals with no symptoms of infection and performing the same laboratory techniques described above.
Complications
  • S. aureus can cause toxin-mediated diseases, such as toxic shock syndrome (TSS), staphylococcal food poisoning (SFP), and staphylococcal scalded-skin syndrome (SSSS). TSS is a rare but serious infection that was originally linked with tampon use. It also can occur after bacteria penetrate the skin after a cut or surgical procedure. Symptoms include the sudden onset of a high fever, diarrhea, headache, and muscle aches. Skin and internal organ damage occur because of toxins released by the bacteria.
  • SFP is a common type of food poisoning. Many types of foods can become contaminated with bacteria that produce toxins. Contamination usually occurs in foods that are not kept hot or cold enough. Symptoms appear suddenly and may include nausea, vomiting, and diarrhea. Most people recover completely in two to three days.
  • SSSS appears as a sloughing of an area of skin that turns into a reddish, infected area. Similar to TSS and SFP, the skin damage is caused by a toxin released by the bacteria. The infection occurs mainly in children and newborns. It is rare in adults. Usually, the infected area heals in one to two weeks.
Treatment
  • Staphylococcal skin infections, including MRSA, usually first appear as small red bumps, which can quickly develop into abscesses that require surgical drainage.
  • Antibiotic resistance appears to occur through spontaneous genetic mutations in the bacteria. These mutations reduce the sensitivity of a bacterium to a given antibiotic or class of antibiotics. A single mutation may impart resistance to an antibiotic, but multiple mutations appear to be required for resistance to other drugs.
  • Antibiotic resistance ranges from none (complete sensitivity) to high. In the face of life-threatening infections, a combination of antibiotics is often given to reduce the chance of an infection worsening because of antibiotic resistance.
  • Following the emergence of MRSA, the antibiotic vancomycin became the drug of choice for treating MRSA infections. However, there are now strains of MRSA that have become resistant to vancomycin as well. Other antibiotics used to treat MRSA include teicoplanin, linezolid, and daptomycin.
Prevention
  • To effectively reduce the incidence of antibiotic resistance, it is necessary to reduce the antibiotic pressure in the bacterial environment, such as the intestinal tract, water supply, and animal reservoirs. Reducing the inappropriate use of antibiotics will reduce antibiotic pressure in the intestinal tract. Improved sanitary treatment of a community's water supply will reduce the antibiotic pressure in this area. Reduction of antibiotic pressure in animal reservoirs is a complex topic and involves identifying and destroying infected animals as well as reducing human contact with animals that might be reservoirs.
  • In the hospital setting, basic infection control practices, such as hand washing and the use of gloves, are essential to the prevention and control of methicillin-resistant Staphylococcus aureus (MRSA) and other drug-resistant organisms. Hospitalized patients diagnosed with MRSA are placed in isolation to minimize the spread of the organism.
References
  1. Buehlmann M, Frei R, Fenner L, et al. Highly effective regimen for decolonization of methicillin-resistant Staphylococcus aureus carriers. Infect Control Hosp Epidemiol. 2008 Jun;29(6):510-6.
    View Abstract
  2. Centers for Disease Control and Prevention (CDC): Community-associated methicillin resistant Staphylococcus aureus. .
  3. Chen XY, Liu XM, Feng LL, et al. Changes and clinical significance of serum Apelin in patients with severe sepsis and septic shock. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2008 Apr;30(2):131-5.
    View Abstract
  4. Chuck EA, Frazee BW, Lambert L, et al. The benefit of empiric treatment for methicillin-resistant staphylococcus aureus. J Emerg Med. 2008 May 29.
    View Abstract
  5. Exline MC, Crouser ED. Mitochondrial mechanisms of sepsis-induced organ failure. Front Biosci. 2008 May 1;13:5030-41.
    View Abstract
  6. Garcia-Vidal C, Sabé NF, Carratalà J, et al. Early mortality in patients with community-acquired pneumonia: causes and risk factors. Eur Respir J. 2008 May 28.
    View Abstract
  7. Grayson ML, Jarvie LJ, Martin R, et al. Significant reductions in methicillin-resistant Staphylococcus aureus bacteraemia and clinical isolates associated with a multisite, hand hygiene culture-change program and subsequent successful statewide roll-out. Med J Aust. 2008 Jun 2;188(11):633-40.
    View Abstract
  8. Groeneveld AB, Hack CE. The role of the innate immune response in hospital- versus community-acquired infection in febrile medical patients. Int J Infect Dis. 2008 May 29.
    View Abstract
  9. Kuo DC, Chasm RM, Witting MD. Emergency department physician ability to predict methicillin-resistant Staphylococcus aureus skin and soft tissue infections. J Emerg Med. 2008 May 29.
    View Abstract
  10. Malik H, Sur B, Singhal N, et al. Antimicrobial protein from Streptomyces fulvissimus inhibitory to methicillin resistant Staphylococcus aureus. Indian J Exp Biol. 2008 Apr;46(4):254-7.
    View Abstract
  11. Natural Standard: The Authority on Integrative Medicine. . Copyright © 2008.
  12. Takeuchi F, Baba T, Hiramatsu K. et al. Comparative analysis of MRSA. Methods Mol Biol. 2007;391:153-68.
    View Abstract
  13. Tang J, Zhou R, Shi X, et al. Two thermostable nucleases coexisted in Staphylococcus aureus: evidence from mutagenesis and in vitro expression. FEMS Microbiol Lett. 2008 May 26.
    View Abstract
  14. Van Den Bossche MJ, Devriendt D, Weyne L, et al. Primary peritonitis combined with streptococcal toxic shock syndrome following an upper respiratory tract infection caused by Streptococcus pyogenes. Ned Tijdschr Geneeskd. 2008 Apr 12;152(15):891-4.
    View Abstract
  15. Wong HR, Cvijanovich N, Wheeler DS, et al. Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock. Am J Respir Crit Care Med. 2008 May 29.
    View Abstract